Tissue Therapies Limited  

(Public, ASX:TIS)   Watch this stock  
Find more results for TIS
-0.010 (-3.70%)
Delayed:   2:09PM GMT+10
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.26 - 0.27
52 week 0.14 - 0.39
Open 0.27
Vol / Avg. 53,288.00/93,709.00
Mkt cap 68.23M
P/E     -
Div/yield     -
EPS -0.03
Shares 262.44M
Beta     -
Inst. own     -

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -4659.63% -2041.14%
Operating margin -4771.17% -2117.51%
EBITD margin - -2088.01%
Return on average assets -34.81% -39.96%
Return on average equity -38.10% -46.98%
CDP Score - -


L19, 179 Turbot Street
+61-7-33343900 (Phone)
+61-7-33343999 (Fax)

Website links


Tissue Therapies Limited is an Australia-based biotechnology company. The Company�s is principally engaged in the research, development and commercialization of the Company�s international intellectual property in wound healing and tissue regeneration. The Company is commercializing VitroGro ECM, is a new treatment for hard to heal wounds that is used in conjunction with standard care, including moist wound dressing and compression. On January 23, 2012, Tissue Therapies Europe Limited a wholly owned subsidiary was set up to provide administration support to Tissue Therapies Limited (Parent Entity). The Company's customers are located predominantly in Australia.

Officers and directors

Steven J. Mercer Chief Executive Officer, Managing Director, Executive Director
Drummond McKenzie Chief Financial Officer, Company Secretary
Zee Upton Chief Scientific Officer
Andrew Thelwell Managing Director - EU Commercial Operations
Eva-Lisa Heinrichs Medical Director - Global Medical Affairs
Saskia Jo Corporate Accountant
Nigel Johnson Operations Director
Hedie Meka Regulatory & Intellectual Property Manager
Gary Shooter Director of Research and Development
Brian Ziegelaar International Product Manager